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Abstract
The	 aim	of	 the	 study	 is	 to	 investigate	 the	patterns	 of	 polypharmacy,	 clinical-rele-
vant	drug-drug	 interactions	 (DDIs),	and	potentially	 inappropriate	medicines	 (PIMs),	
and	whether	polypharmacy,	potential	 serious	clinically-relevant	DDIs,	or	PIMs	can	
be	associated	with	 low	quality	of	 life	 (QoL)	 index	scores	of	older	adults	with	 type	
2	diabetes	(T2D).	A	cross-sectional	study	was	conducted	using	data	of	670	elderly	
T2D	sub-cohort	 from	a	nationwide	pharmacy-based	 intensive	monitoring	study	of	
inception	cohort	of	T2D	in	Portugal.	72.09%	were	found	on	polypharmacy	(≥5	medi-
cines).	Participants	on	polypharmacy	were	mostly	females	(P	=	.0115);	more	obese	
(P	=	.0131);	have	more	comorbid	conditions	(P	<	.0001);	more	diabetes	complications	
(P	<	.0001);	and	use	more	of	glucose	lowering	drugs	(P	=	.0326);	insulin	(P	<	.0001);	
chronic medicines (P	<	 .0001);	and	have	higher	diabetes	duration	 (P	=	 .0088)	than	
those	without	 polypharmacy.	 10.59%	of	 the	 participants	were	 found	 to	 have	 po-
tential	serious	clinically	relevant	DDIs.	The	most	frequent	drug-combinations	were	
angiotensin-converting	enzyme	(ACE)	inhibitors	with	angiotensin-receptor	blockers	
(ARBs),	aspirin	with	Selective	serotonin	reuptake	inhibitors	(SSRIs),	and	clopidogrel	
with	calcium	channel	blockers.	PIMs	are	 found	 in	36.11%	of	 the	participants.	The	
most	common	PIMs	were	benzodiazepines,	long-acting	sulfonylureas,	and	iron	over-
dose.	The	adjusted	multivariate	models	show	that	Polypharmacy,	PIMs,	and	potential	
serious	 clinically	 relevant	DDIs	were	 associated	with	 lower	QoL	 index	 scores	 (OR	
1.80	95%	CI	1.15-2.82),	(OR	1.57	95%	CI	1.07-2.28),	and	(OR	1.34	95%	CI	0.73-2.48)	
respectively.	The	study	shows	that	polypharmacy,	potential	serious	clinical-relevant	
DDIs,	and	PIMs	may	correlate	with	risk	of	reduced	health	related	QoL	outcome	of	
older adults with T2D.
K E Y W O R D S
drug-drug	interactions,	elderly,	polypharmacy,	potentially	inappropriate	medicines,	quality	of	
life,	Type	2	diabetes
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1  | INTRODUC TION
The	 prevalence	 of	 elderly	 people	 with	 type	 2	 diabetes	 (T2D)	 has	
been	increasing	globally.	In	2018,	it	was	estimated	that	there	were	
more	than	500	million	people	diagnosed	with	T2D,1 and more than 
half were elderly.2	Elderly	people	with	T2D	are	at	higher	risk	of	poly-
pharmacy as result of multimoridity and aging.3
Polypharmacy	can	be	associated	with	several	unintended	thera-
peutic outcomes such as increasing the incidence of potential serious 
drug-drug	interactions	(DDIs)	that	can	be	harmful	and	life-threaten-
ing	and	use	of	potentially	inappropriate	medicines	(PIMs).4-7
Despite	that,	there	is	a	paucity	in	addressing	the	risk	of	poten-
tial	clinically	relevant	serious	DDIs	and	PIMs.	Only	one	study	found	
that at least one potential serious clinically relevant DDIs was found 
(7.10%),8	 and	 two	 studies	 found	 that	 the	 prevalence	 of	 PIMs	was	
found	 between	 (22.70%-68.10%).9,10	 Moreover,	 there	 is	 a	 lack	 of	
evidence on whether the presence of polypharmacy and its conse-
quences	can	impact	quality	of	life	(QoL).
Therefore,	the	aims	of	this	study	was	to	investigate	the	patterns	
of	 polypharmacy,	 clinical-relevant	 DDIs,	 and	 PIMs,	 and	 whether	
polypharmacy,	potential	serious	clinically-relevant	DDIs	or	PIMs	can	
be	associated	with	low	QoL	index	scores	of	older	adults	with	T2D.
2  | METHODS
A	cross-sectional	 study	was	 conducted	using	 the	 baseline	 data	 of	
elderly	(aged	65	years	or	more)	cohort	from	a	nationwide	pharmacy-
based intensive monitoring study of inception cohort of T2D pa-
tients	 using	 the	 recently	 launched	 glucose	 lowering	 drugs	 (GLDs).	
Pharmacists	and	participants	recruitment	procedures	have	been	de-
scribed in detail elsewhere.11
Invitation letters were sent to all pharmacies from the National 
Association	of	Pharmacies	 that	satisfied	 the	 inclusion	criteria.	The	
pharmacists who agreed to participate were invited to attend a 
training	session	in	which	the	study	was	explained.
The eligible study population consisted of first users of the new 
GLD	 (defined	 as	 users	 who	 did	 not	 take	 the	 inception-monitored	
drug	within	the	6	months	prior	to	recruitment,	as	self-reported	by	
the	patients)	that	were	reimbursed	in	Portugal	at	the	time	of	enroll-
ment:	dipeptidyl	peptidase-4	inhibitor	(DPP-4)	alone	or	in	fixed-dose	
combination	with	metformin,	glucagon	like	peptide	1	receptor	ago-
nists	(GLP-1	ra),	or	sodium-glucose	transport	protein	2	(SLGT-2).	In	
this	context,	the	inception	drug	corresponded	to	the	GLD	within	the	
monitored	therapeutic	classes	 (DPP-4,	GLP-1	ra,	or	SLGT-2)	which	
the patient was identified with at cohort entry.
The cohort was divided into two subgroups according to partic-
ipants’	T2D	treatment	experience:	incident	new	users;	participants	
who were using one of the monitored drugs for the first time and had 
no	current	or	prior	experience	with	DPP-4,	GLP-1	ra,	or	SGLT2	and	
prevalent new users; participants who had previously used or were 
still	using	least	one	drug	of	the	monitored	treatment	classes:	DPP-4,	
GLP-1	ra,	or	SGLT2,	but	not	the	inception	GLD.
At	 recruitment,	 participants	 had	 a	 structured	 face-to-face	 in-
terview with a trained pharmacist to collect the sociodemographic 
data	(birth	date,	gender,	highest	educational	level	completed,	co-res-
idence	status,	and	number	of	people	 living	 in	 the	subject's	house-
hold),	 anthropometric	 data	 (weight	 and	 height	 were	measured	 by	
pharmacy	staff	to	calculate	the	body	mass	index	[BMI])	which	was	
categorized	as	underweight	(<18.50	kg/m2),	normal	(18.50-24.99	kg/
m2),	overweight	 (25.00-29.99	kg/m2),	and	obese	 (≥30	kg/m2).	Self-
reported data were collected on clinical characteristics (age at time 
of	T2D	diagnosis,	clinical	care	setting),	T2D	treatment,	T2D	related	
complications,	co-morbidities,	and	concomitant	therapy.
2.1 | Data analysis
Study	participants	were	divided	 into	 two	subgroups	according	 the	
presence	or	absence	of	polypharmacy.	Polypharmacy	was	defined	as	
the	use	of	five	or	more	medicines,	which	is	the	most	widely	accepted	
definition in the literature.12
The	 medicines	 used	 were	 checked	 for	 the	 DDIs	 using	 IBM	
Micromedex	 Platform	 (IBM®	 Corporation,	 2019).13 This platform 
classify them according to their severity as: contraindicated-the	
drugs are contraindicated for concurrent use; major interaction 
potential	 life-threatening	 and/or	 requiring	medical	 intervention	 to	
minimize	or	prevent	serious	adverse	effects;	moderate interaction—
may	result	in	exacerbation	of	the	patient's	condition	and/or	require	
an alteration in therapy; and minor	 interaction-would	have	 limited	
clinical	effects,	and	generally	would	not	 require	a	major	alteration	
in	 therapy.	Micromedex	 platform	 also	 addresses	 the	 potential	 ad-
verse	effect	of	the	interaction,	mechanism	of	the	interaction,	onset	
of	the	interaction,	rate	of	scientific	evidence	(Excellent/Good/Fair/
Unknown),	and	the	proposed	clinical	management	of	the	interaction.
What is already known about this subject
•	 Polypharmacy	 is	 common	 among	 the	 elderly	 with	
diabetes.
•	 Lack	of	studies	addressing	the	serious	clinically	relevant	
drug-drug	 interactions	 (DDIs)	 and	 potentially	 inappro-
priate	medicines	(PIMs)	in	elderly	with	type	2	diabetes.
•	 Lack	of	evidence	if	polypharmacy	and	its	consequences	
can	 impact	quality	of	 life	 (QoL)	of	 elderly	with	 type	2	
diabetes.
What this study adds
•	 72.09%	of	study	cohort	are	on	polypharmacy	with	poor	
socio-demographic	profile.
•	 10.59%	have	potentially	serious	clinically	relevant	DDIs	
and	36.11%	have	PIMs.
•	 Polypharmacy	and	its	negative	consequences	may	asso-
ciate	with	poor	QoL.
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We	 defined	 potentially	 serious	 clinically	 relevant	 DDIs	 as	
those having a severity of major	 drug-drug	 interaction	or	when	
the drug combination is contraindicated with scientific evi-
dence rating of excellent (defined as controlled studies that have 
clearly	established	the	existence	of	the	interaction)	according	to	
Micromedex.
PIMs	were	identified	using	STOPP	criteria	version	2,	the	final	list	
included	80	STOPP	criteria,	was	agreed	after	two	rounds	of	Delphi	
validation,	which	was	arranged	according	 to	 the	physiological	 sys-
tems of the body for ease of use and rapid application.14
In	terms	of	predictive	validity,	it	modestly	discriminates	for	out-
comes	such	as	adverse	drug	events,	emergency	department	visits,	
and	hospital	admissions.	The	STOPP	criteria	version	2	has	a	high	sen-
sitivity	in	detecting	PIMs	and	good	inter-rater	reliability.15-17
The	QoL	was	measured	 using	 the	 three-level	 EuroQol	 five-di-
mensional	 (EuroQol	5-D-3L)	questionnaire.	The	EQ-5D	encompass	
five	dimensions	 influencing	health	 (mobility,	 self-care,	usual	activi-
ties,	pain/discomfort,	anxiety/depression)	each	with	three	levels	of	
functioning	 (first	 level;	 no	 problem,	 second	 level;	 some	 problems,	
third	level;	severe	problems).
The	 summary	 scores	was	 computed	 to	Portuguese	 preference	
weighted	EQ-5D	index	scores	using	Portuguese	values	set.18	After	
that,	the	study	participants	finished	the	EQ-5D	visual	analogue	scale	
(VAS).	In	the	VAS,	the	patients	evaluated	their	current	health	state	
on scale between zero	(worst	possible	health	state)	to	one hundred 
(best	possible	health	state),	the	high	scores	index	together	with	high	
VAS	suggest	best	health	state.19
2.2 | Statistical analysis
A	database	was	created	including	information	on	sociodemographic	
characteristics,	 comorbidities,	 and	 prescribed	 medicines	 including	
both	T2D	and	other	chronic	medicines,	potential	(contraindication,	
serious,	moderate,	and	minor)	DDIs,	and	PIMs.	Data	were	described	
as	absolute	and	relative	counts	and	means	(±	SD).
A	multivariate	binary	 logistic	regression	model	was	used	to	as-
sess	the	adjusted	associations	between	polypharmacy,	potential	se-
rious	 clinically	 relevant	DDIs,	 PIMs,	 and	 lower	QoL	 scores.	 Based	
on	Portuguese	elderly	population	preferences,	mean	index	score	of	
QoL	was	considered	(0.60)	as	cut-off	value.20 Results of this analysis 
were	presented	as	adjusted	odds	ratios	 (ORs)	and	their	 respective	
95%	confidence	 intervals	 (CIs).	Data	analysis	was	performed	using	
SAS®	software.
3  | RESULTS
3.1 | Characteristics of study population
Of	 the	1328	adults	with	T2D	recruited	 in	 the	original	cohort,	670	
were elderly people with T2D included in the current study. Of 
these,	 483	 (72.09%)	 were	 on	 polypharmacy.	 Among	 those	 on	
polypharmacy,	75.57%	 (n	=	365)	and	24.43%	 (n	=	118)	were	using	
5-9	and	≥10	different	medicines	respectively.
Participants	 on	 polypharmacy	were	 significantly	more	 females	
(P	=	.0115),	more	obese	(P	=	.0131),	had	a	higher	duration	of	diabetes	
(P	 =	 .0088),	more	 comorbid	 conditions	 (P	 <	 .0001),	more	diabetes	
complications (P	<	 .0001),	using	more	GLDs	treatment	(P	=	 .0326),	
insulin use (P	<	.0001),	and	more	chronic	medicines	(P	<	.0001)	com-
pared	to	those	without	polypharmacy	(Table	1).
3.2 | Identification of potentially serious clinically 
relevant DDIs
Of	670	elderly	adults	with	T2D,	71	(10.59%	of	total	cohort)	had	po-
tentially	serious	clinically	relevant	DDIs.	Among	the	most	frequent	
drug-combinations	that	contributed	to	potentially	serious	clinically	
relevant	DDIs	were	angiotensin-converting	enzyme	(ACE)	inhibitors	
with	angiotensin-receptor	blockers	(ARBs)	(24.71%),	aspirin	with	se-
lective	serotonin	reuptake	inhibitors	(SSRIs)	(19.10%)	and	clopidogrel	
with	calcium	channel	blockers	(13.84%;	Figure	1).	The	full	descrip-
tion	of	these	DDIs	is	presented	in	(Table	S2).
3.3 | Identification of potentially 
inappropriate medicines
Of	the	study	cohort,	242	(36.11%)	had	at	least	one	PIMs.	Of	these,	
176	(72.72%)	had	one	PIM,	49	(20.24%)	had	two	PIMs,	and	17	had	
more	than	two	PIMs	 (7.02%).	The	mean	of	PIMs	was	 (1.36	±	0.78)	
per patient.
The	 most	 prevalent	 PIMs	 were	 benzodiazepines	 (43.50%),	
long-acting	sulfonylureas,	glibenclamide	or	glimepiride	(9.37%),	and	
higher	dose	of	iron	supplements	(4.83%;	Figure	2).	The	full	descrip-
tion	of	PIMs	is	presented	in	Table	S3.
3.4 | Quality of life
Elderly	 patients	 with	 T2D	 in	 the	 study	 who	 were	 on	 polyphar-
macy have some to more severe problems in mobility (P	=	.0004),	
usual activity (P	=	.0001),	personal	care	(P	=	.0001),	pain	(0.0007),	
and	 anxiety	 and	 depression	 (P	 =	 .0365),	 low	 mean	 VAS	 score	
(63.19	 ±	 21.24	 vs	 69.30	 ±	 19.97,	P	 <	 .0001)	 and	 low	mean	 index	
score	(0.58	±	0.32	vs	0.72	±	0.24,	P	<	.0001),	compared	with	those	
not on polypharmacy.
The elderly people with T2D with potentially serious clinically rel-
evant	DDI	have	less	problems	in	all	EuroQol	5-D-3L	dimensions,	but	
with	low	mean	VAS	score	(62.00	±	20.56	vs	65.16	±	21.11,	P	=	.3466)	
and	low	index	score	(0.54	±	0.37	vs	0.63	±	0.29,	P	=	.0637)	compared	
with those without potential serious clinically relevant DDIs.
Elderly	people	with	T2D	with	at	least	one	PIM	have	some	to	se-
vere problems in mobility (P	=	.0346),	and	pain	(P	=	.0031),	with	low	
mean	VAS	score	(62.32	±	21.89	vs	66.33	±	20.45,	P	=	.0387)	and	low	
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TA B L E  1   Descriptive characteristics of study population according to polypharmacy
Characteristics Total sample (N = 670)
T2DM on Polypharmacy 
(N = 483)
T2DM Not on Polypharmacy 
(N = 187) P value
Gender	M/F	(%) 338/332	(50.45/49.55) 229/254	(47.41/52.59) 109/78	(58.29/41.71) P = .0115
Age	(Mean	±	SD) 73.01	±	6.22 73.21	±	6.22 72.50	±	6.22 P = .2606
65-74	(%) 432	(64.48) 303	(62.73) 129	(68.99)
75-84	(%) 203	(30.30) 152	(31.47) 51	(27.27)
≥85	(%) 35	(5.22) 28	(5.80) 7	(3.74)
BMI	(%) P = .0131
Underweight	
(<18.5	kg/m2)
2	(0.29) 2	(0.41) 0	(0)
Normal 
(18.5-24.99	kg/m2)
108	(16.12) 77	(15.94) 31	(16.58)
Preobese	
(25-29.99	kg/m2)
277	(41.34) 185	(38.30) 92	(49.20)
Obese	(≥30	K/m2) 265	(39.55) 207	(42.86) 58	(31.02)
NR	=	(18) NR	=	(12) NR	=	(6)
Educational	level	(%) P	=	.7507
No	Education 128	(19.10) 95	(19.67) 33	(17.65)
Primary	(1-9	y) 425	(63.43) 304	(62.94) 121	(64.71)
Secondary	(10-12	y) 54	(8.06) 42	(8.70) 12	(6.42)
Superior	(>12	y) 41	(6.12) 29	(6) 12	(6.42)
NR	=	(22) NR	=	(13) NR	=	(9)
Occupation	(%) P	=	.9262
Employed 21	(3.13) 16	(3.31) 5	(1.04)
Unemployed 4	(0.60) 3	(0.62) 1	(0.53)
Retired 605	(90.29) 434	(89.86) 171	(91.44)
Domestic 37	(5.52) 28	(5.80) 9	(4.81)
NR	=	(3) NR	=	(2) NR	=	(1)
Living	alone P	=	.5906
Yes 135	(20.14) 100	(20.70) 35	(18.71)
No 531	(79.25) 381	(78.88) 150	(80.21)
NR	=	(4) NR	=	(2) NR	=	(2)
Duration	of	diabetes	(%) P	=	.0088
Less	than	one	year 57	(8.50) 34	(7.04) 23	(12.30)
≥1-<3	y 52	(7.76) 32	(6.63) 20	(10.70)
≥3-<6	y 85	(12.68) 64	(13.25) 21	(11.23)
≥6-<10	y 77	(11.49) 54	(11.18) 23	(12.30)
≥10	y 348	(51.94) 272	(56.31) 76	(40.64)
NR	=	(44) NR	=	(20) NR	=	(24)
Healthcare	setting	(%) P	=	.1821
Primary	care 469	(70.00) 331	(68.53) 138	(73.80)
NonPrimary	care 201	(30.00) 152	(31.47) 49	(26.20)
Comorbidities	(%) P < .0001
Yes 629	(93.88) 470	(97.31) 159	(85.03)
No 41	(6.12) 13	(2.69) 28	(14.97)
Comorbid	conditions	(%)
Hypertension 531	(79.25) 409	(84.68) 122	(65.24) P < .0001
(Continues)
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Characteristics Total sample (N = 670)
T2DM on Polypharmacy 
(N = 483)
T2DM Not on Polypharmacy 
(N = 187) P value
Renal failure 72	(10.74) 63	(13.04) 9	(4.81) P = .0200
Heart failure 125	(18.65) 108	(22.36) 17	(3.52) P < .0001
Dyslipidaemia 398	(59.40) 326	(67.49) 72	(14.91) P < .0001
Thyroid gland 24	(3.58) 21	(4.35) 3	(1.60) P	=	.0865
Respiratory system 25	(3.73) 21	(4.35) 4	(2.14) P	=	.1760
Digestive system 31	(4.62) 27	(14.44) 4	(2.14) P = .0565
Musculoskeletal 
system
19	(2.83) 17	(3.52) 2	(1.07) P	=	.0866
Prostate	hyperplasia 21	(3.13);	NR	=	(332) 13	(2.69);	NR	=	(254) 8	(4.28);	NR	=	(78) P	=	.5539
Neoplasms 23	(3.43) 14	(2.90) 9	(4.81) P = .2222
Depression 11	(1.64) 7	(1.45) 4	(2.14) P	=	.5286
Hyperuricemia 16	(2.38) 15	(3.11) 1	(0.53) P = .0506
Other 79	(11.79) 67	(13.87) 12	(6.42) P	=	.0073
Diabetes	complications	(%) P < .0001
Yes 179	(26.71) 151	(31.26) 28	(14.97)
No 482	(71.94);	NR	=	(9) 326	(67.49);	NR	=	(6) 156	(83.42);	(NR	=	3)
Retinopathy	(%) 120	(17.91) 103	(21.33) 17	(9.09) P = .0002
Nephropathy	(%) 74	(11.04) 65	(13.46) 9	(4.81) P = .0014
Diabetic	Foot	(%) 39	(5.82) 35	(7.25) 4	(2.14) P = .0116
Diabetes	Medicines	(%)
Oral	GLD	treatment 670	(100) 483	(100) 187	(100) P = .0326
Insulin 117	(17.46) 106	(21.95) 11	(5.88) P < .0001
Chronic	medicines	(%) P < .0001
Yes 458	(68.35) 365	(75.57) 93	(49.73)
No 193	(28.80);	NR	=	(19) 118	(24.43) 75	(40.11);	NR	=	(19)
Renin-angiotensin	
system medicines
458	(68.35) 365	(75.57) 93	(49.73) P < .0001
Beta-blocking	agents 173	(25.28) 161	(33.33) 12	(6.42);	NR	=	(19) P < .0001
Diuretics 172	(25.67) 160	(33.13) 12	(6.42);	NR	=	(19) P < .0001
Calcium channel 
blockers
144	(21.49) 130	(26.92) 14	(7.49);	NR	=	(19) P < .0001
Lipid	lowering	
medicines
398	(59.40) 343	(71.01) 55	(29.41) P < .0001
Anti-thrombotic 259	(38.65) 239	(49.48) 20	(10.70);	NR	=	(19) P < .0001
Acid	related	disorders	
medicines
212	(31.64) 196	(40.58) 16	(8.56);	NR	=	(19) P < .0001
Psycholeptics 167	(24.92) 153	(31.68) 14	(7.49);	NR	=	(19) P < .0001
Psychoanaleptics 114	(17.01) 102	(21.12) 12	(6.42);	NR	=	(19) P < .0001
Potentially	serious	
clinically relevant 
drug-drug	interactions
71	(10.59) 70	(14.49) 1	(0.53) P < .00001
Potentially	
inappropriate 
medicines
242	(36.11) 219	(45.34) 23	(12.30) P < .00001
Abbreviations:	BMI,	body	mass	index;	NR,	nonrespondents	to	the	questionnaire	in	the	original	study;	GLD,	glucose	lowering	drugs,	these	includes:	
Gliptins	(either	alone	or	in	combination),	GLP-1	agonists,	SGLT2-inhbitors,	or	any	combination	of	any	two	diabetes	study	medicines.
TA B L E  1   (Continued)
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mean	index	score	(0.57	±	0.30	vs	0.65	±	0.30,	P	=	.0003)	compared	
with	those	without	any	PIM	Table	S4.
On	 the	 adjusted	multivariate	 analysis,	 polypharmacy,	 potential	
serious	clinically	relevant	DDIs	and	PIMs	were	associated	with	lower	
index	 scores	 (OR	 1.80	 95%	CI	 1.15-2.82),	 (OR	 1.34	 95%	CI	 0.73-
2.48),	and	(OR	1.57	95%	CI	1.07-2.28)	respectively	(Table	2).
4  | DISCUSSION
This study show high prevalence of polypharmacy in a cohort of 
elderly people with T2D when comparing to other countries such 
as	Sweden	(56.70%),21	Italy	(57.10%),22	and	Greece	(22.50%).23 This 
can	be	explained	by	a	higher	overall	prevalence	of	polypharmacy	in	
older	population	with	chronic	diseases	in	Portugal.24
Polypharmacy	was	more	 prevalent	 in	 the	 elderly	women	with	
T2D. This finding was reported in previous studies.25-27	It	can	be	ex-
plained that women tend to be more concerned about their health 
and seek health services more often.27
Obesity	 was	 associated	 with	 polypharmacy,	 a	 finding	 also	 in	
agreement	with	pre-existing	 literature,22,28 which could be due to 
the presence of multimorbid conditions.28,29
Duration	of	diabetes,	presence	of	comorbid	conditions	and	dia-
betes complications were associated with polypharmacy. T2D itself 
with	wide	array	of	comorbidities	such	as	hypertension,	dyslipidae-
mia,	and	heart	failure,	in	addition	to	renal	complications	can	increase	
the chance of multiple medicines use.30
10.59%	 of	 the	 study	 cohort	 were	 found	 to	 have	 potentially	
serious	 clinically	 relevant	 DDIs,	 which	 is	 considered	 higher	 than	
previously	 reported	 (7.10%).8	However,	 a	direct	 comparison	 is	un-
attainable due to the differences in comorbid conditions and med-
icines prescribed and different platforms used for assessing DDIs.
These harmful potential interactions may result in increased risk 
of	thrombotic	events	from	decreased	antiplatelet	effect	or	bleeding,	
followed by hypotension or renal failure from cardiovascular medi-
cines,	myopathy	with	statin	therapy	and	increased	digoxin	concen-
trations	causing	risk	of	toxicity.
Our results were different from previously reported study by 
Dumbreck and colleagues who selected three clinical guidelines 
produced	by	the	National	 Institute	for	Health	and	Care	Excellence	
(NICE)	 including	T2D,	and	systematically	 looked	for	potentially	se-
rious	DDIs	in	relation	to	another	11	NICE	guidelines	found	that	the	
most common category was cardiovascular related harm such as sig-
nificant	hypotension	or	bradycardia,	followed	by	increased	lithium	or	
digoxin	concentrations	causing	risk	of	toxicity,	myopathy	with	statin	
treatment,	and	renal	or	serum	potassium	associated	harms.31
The most common medicine class combinations involved in 
potential	 serious	 clinically	 relevant	DDIs	were	 ACE	 inhibitors	 and	
ARBs.	Prescribers	seem	to	be	less	aware	of	the	risk	from	this	combi-
nation,	as	it	counts	for	more	than	(24%)	of	the	total	potential	serious	
clinically relevant DDIs.
F I G U R E  1  Prevalence	of	drug	combinations	that	contributed	to	
potentially	serious	clinically	relevant	drug-drug	interactions
F I G U R E  2  The	Prevalence	of	potentially	inappropriate	
medicines according to the organ system or medicine class
TA B L E  2  Results	of	adjusted	multivariate	models	analyzing	polypharmacy	with	quality	of	life	(QoL),	potential	serious	clinically	relevant	
drug-drug	interactions,	and	potentially	inappropriate	medicines	with	QoL
Model 1 Model 2 Model 3
Parameter OR 95% CI Parameter OR 95% CI Parameter OR 95% CI
Polypharmacy 1.80 1.15-2.82 Potential	serious	
clinically relevant DDIs
1.34 0.73-2.48 PIM 1.57 1.07-2.28
Male 0.47 0.32-0.68 Male 0.45 0.31-0.66 Male 0.47 0.33-0.69
Age	(74-85) 1.63 1.08-2.47 Age	(74-85) 1.66 1.10-2.50 Age	(74-85) 1.66 1.10-2.52
Obesity 1.89 1.09-3.27 Obesity 1.92 1.11-3.32 Obesity 1.97 1.14-3.41
Chronic conditions 3.44 1.24-9.58 Chronic conditions 4.25 1.56-11.59 Chronic conditions 4.04 1.47-11.09
Complications 2.06 1.34-3.16 Complications 2.14 1.40-3.28 Complications 2.18 1.42-3.35
Abbreviation:	PIM,	potentially	inappropriate	medicine.
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Both	 (VALIANT)	 and	 (ONTARGET)	 trials	 revealed	 that	 concur-
rent	use	of	both	ACE	inhibitors	and	ARBs	was	not	associated	with	
reduce	 the	 risk	 of	 death	 from	 cardiovascular	 causes,	 myocardial	
infarction,	 stroke	or	hospitalization	 from	heart	 failure	but	had	sig-
nificantly	increased	risk	of	hypotension,	syncope,	renal	dysfunction,	
and	hyperkalemia,	with	a	trend	toward	an	increased	risk	of	renal	dys-
function requiring dialysis.32,33
Clopidogrel was the most prevalent interacting medicine in-
volved	in	potential	serious	clinically	relevant	DDIs	(24.71%).	This	can	
be	explained	by	higher	prevalence	of	heart	diseases	and	use	of	an-
tiplatelet agents.
Concurrent use of clopidogrel and proton pump inhibitors may 
be	 associated	 with	 high-risk	 of	 thrombotic	 events.	 A	 recent	 me-
ta-analysis	 found	that	 this	combination	 is	associated	with	 increase	
in composite major adverse cardiac events which is a composite out-
come	typically	comprised	of	non-fatal	myocardial	infarction,	non-fa-
tal	 stroke,	 and	 cardiovascular	 death	 (HR	 1.28;	 95%	 CI	 1.24-1.32),	
myocardial	 infarction	 (HR	1.51;	 95%	CI	 1.40-1.62)	 and	 stroke	 (HR	
1.46;	95%	CI	1.15-1.86).34
Interaction between calcium channel blockers and clopidogrel 
can	be	also	associated	with	reduced	clopidogrel	effect.	Nevertheless,	
there	are	controversies	in	the	literature,	since	some	studies	found	a	
reduction	in	the	effect	of	clopidogrel	with	this	combination,35,36 and 
other studies could not establish any evidence of reduction in the 
anti-platelet	activity	of	clopidogrel.37,38
The	prevalence	of	PIMs	was	found	to	be	36.11%.	This	finding	is	
in	agreement	with	previous	studies	(22.70%-68.10%).9,10 Comparing 
to	the	literature,	our	findings	show	high	prevalence	of	benzodiaze-
pines	use	(43.50%	vs	5.9%-14.80%).9,10
Benzodiazepines	 are	 associated	 with	 a	 higher	 risk	 of	 falls	 in	
older adults.39	A	 study	conducted	 in	 Ireland	 found	 that,	 the	use	
of	 benzodiazepines	was	 associated	with	 serious	 falls	when	 cou-
pled	with	polypharmacy	(adjusted	relative	risk	[aRR]	1.40,	95%	CI	
1.04-1.87),	and	associated	with	a	greater	number	of	falls	(adjusted	
incident	rate	ratio	(aIRR)	1.32,	95%	CI	1.05-1.65),	independent	of	
polypharmacy.40
The	 use	 of	 long-acting	 sulfonylureas	was	 the	 2nd	major	 PIMs	
(9.37%)	reported.	Previous	study	found	that	the	use	of	these	long-act-
ing sulfonylureas was associated with increased risk of hip fracture 
(aOR	1.46,	95%	CI	1.17-1.82)	and	 the	 risk	become	higher	 in	 those	
with	documented	hypoglycemia	(aOR	2.42,	95%	CI	1.35-4.34).41
The use of higher doses of oral elemental iron was also reported 
in	 the	study	 (4.83%),	which	can	be	associated	with	abdominal	dis-
comfort,	nausea,	vomiting,	changes	in	bowel	movements,	and	black	
stools.42
The study revealed that polypharmacy (using 5 or more medi-
cines)	 was	 associated	 with	 increased	 risk	 of	 low	QoL.	 A	 study	 in	
Spain	of	elderly	population	 (52.50%	of	them	with	T2D)	found	that	
the	of	poor	QoL	was	only	associated	when	polypharmacy	defined	as	
the use of 10 or more medicines.43
In	 addition,	 the	 study	 found	 that	 the	 presence	 of	 at	 least	 one	
potentially	 inappropriate	 medicine,	 and	 potential	 clinically	 rele-
vant DDIs can be associated with increasing the risk of poor health 
related	QoL	in	elderly	with	T2D.	To	the	best	of	our	knowledge,	these	
results have not previously been reported.
Previous	study	by	Antonio De Vincentis and colleagues found that 
only	polypharmacy	which	considered	as	simple	measure	surpass	PIM	
and DDI indicators of quality of therapy as it correlate of primary 
clinical	outcomes,	that	are	mortality	and	rehospitalization44
Some	 limitations	were	present	 in	 the	 study.	Presence	of	 infor-
mation	bias	which	is	characterized	by	inaccuracy	of	exact	comorbid	
condition diagnosis and data regarding lab results (eg estimated glo-
merular	filtration	rate)	were	not	reported.	The	data	analysed	in	the	
present	study	were	baseline	data,	and	we	do	not	know	whether	the	
patients really consumed all the dispensed medicines.
The	DDIs	found	in	this	study	were	only	potential;	in	other	words,	
no	 actual	 outcomes	or	 consequences	were	 evaluated.	 Finally,	 due	
to	the	nature	of	the	cross-sectional	design,	we	could	not	have	the	
opportunity	 to	explore	 the	 impact	of	polypharmacy	on	 symptoms	
burden	or	QoL	over	time.
This study reveals that polypharmacy is common and highly 
prevalent	in	cohort	of	elderly	people	with	T2D,	which	can	be	due	to	
disease burden and presence of multimorbid conditions.
The prevalence of potential serious clinically relevant DDIs are 
relatively low and the medicines concerned are few. The monitoring 
of patients treated with clopidogrel and other cardiovascular medi-
cines should be improved.
Great	attention	should	be	considered	while	prescribing	two	dif-
ferent class of cardiovascular medicines with synergism effect that 
could	have	potential	impact	renal	function	and	electrolyte	balance,	
especially	in	elderly.	Precise	and	updated	information	on	interacting	
drugs	could	prevent	the	occurrence	of	known	interactions,	particu-
larly	when	therapeutic	alternatives	exist.
Defining	the	clinical	relevance	of	a	DDI	is	extremely	important	
due to the presence of thousands of theoretically potential DDIs. 
High-quality	evidence	to	support	the	existence	of	many	DDIs	is	re-
quired,	which	can	be	established	through	real-world	observational	
studies.
STOPP	criteria	represent	the	more	common	avoidable	instances	
of	 inappropriate	 prescribing	 in	 older	 people	 in	 day-to-day	 clinical	
practice.	Based	on	our	results,	risk	of	fall,	fracture	or	fracture	risk,	
hypoglycemia,	and	even	gastrointestinal	side	effects	can	be	avoided	
if prescribers assessed appropriately those elderly patients’ medi-
cines use.
The	 selection	 and	 use	 of	 PIM	 criteria	 for	 research	 or	 practice	
should be taken into consideration considering the circumstances 
and requirements for each case as the relationships with outcomes 
can be different substantially between tools 45
One of the challenges facing healthcare professionals is that the 
actual	harms	of	both	DDIs	and	PIMs	which	are	poorly	quantified	in	
real-world	populations	in	which	people	are	typically	older,	frail,	have	
more comorbid conditions and receiving more medicines.
Future	studies	should	have	 the	ability	 to	explore	 the	 influence	
of	possible	adverse	drug	events	as	results	of	DDIs	and	PIMs	due	to	
polypharmacy	on	elderly	with	T2D	and	the	impact	on	QoL	over	time	
in	real-world.
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5  | CONCLUSIONS
The use of polypharmacy is highly prevalent among cohort of 
elderly people with T2D. This population is at higher risk of po-
tential	 serious	 clinically	 relevant	 DDIs	 and	 PIMs	 as	 result	 of	
polypharmacy.
The prevalence of potential serious clinically relevant DDIs 
found is relatively low and can be associated with increased risk of 
poorer	QoL,	like	polypharmacy	and	PIMs.
Prospective	 studies	 are	 required	 to	 observe	 the	 clinical	 out-
comes of the potential serious clinically relevant DDIs and presence 
of	PIMs	in	real-world	clinical	practice.	Health	Interventions	includ-
ing	pharmacist's	medication	use	review	and	deprescribing	strategies	
may	help	to	improve	patient-centered	outcomes.
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